Overcoming Temozolomide Resistance in Glioblastoma via Enhanced NAD<sup>+</sup> Bioavailability and Inhibition of Poly-ADP-Ribose Glycohydrolase

Overcoming Temozolomide Resistance in Glioblastoma via Enhanced NAD<sup>+</sup> Bioavailability and Inhibition of Poly-ADP-Ribose Glycohydrolase

Glioblastoma multiforme (GBM) is an incurable brain cancer with an average survival of approximately 15 months. Temozolomide (TMZ) is a DNA alkylating agent for the treatment of GBM. However, at least 50% of the patients treated with TMZ show poor response, primarily due to elevated expression of th...

Full description

Bibliographic Details
Main Authors: Jianfeng Li, Christopher A. Koczor, Kate M. Saville, Faisal Hayat, Alison Beiser, Steven McClellan, Marie E. Migaud, Robert W. Sobol
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Cancers
Subjects:
glioblastoma
NAD<sup>+</sup>
PARG inhibition
PARP activation
temozolomide
MSH6
Online Access:https://www.mdpi.com/2072-6694/14/15/3572

Internet

https://www.mdpi.com/2072-6694/14/15/3572

Similar Items